We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Siemens Publicly Lists Healthcare Business

By Sanjit Dutt
Posted on 14 Nov 2016
Siemens AG (Munich, Germany), Europe’s largest industrial conglomerate, has announced that its USD 15 billion healthcare division, which operates under the uniform brand name Siemens Healthineers (Erlangen, Germany), will be publicly listed as an independent medical technology business.

In May 2014, Siemens had announced its intention to set up its healthcare business as a "company within the company" so that the business could adjust to transformations in the healthcare market in a flexible and focused manner with its own market presence. More...
Siemens Healthineers focuses on the therapeutic and molecular diagnostic market, and offers medical imaging, laboratory diagnostics, and management, consulting and digital services. It is currently working with Pfizer to develop in vitro diagnostic tests for improving patient selection, treatment monitoring and dosing in clinical trials, as well as with ViiV Healthcare for developing diagnostics for its first-in-class HIV drug Celsentri (maraviroc).

Siemens has not yet provided any details about the planned scope and timing regarding the initial public offering of its healthcare business, but expects the move to encourage investors and provide a foundation for any future acquisitions or investments. "Healthcare technology is a highly attractive business in which we want to further expand our leading position. With this step, we continue to implement Vision 2020 launched in May 2014. The public listing will give Healthineers even more focus and flexibility in pursuing its growth strategy," said Joe Kaeser, President and CEO of Siemens AG. "The public listing is now the next step in further strengthening Siemens Healthineers in Siemens for the future. We're implementing this from an already leading position. Siemens Healthineers has already increased its market share and has an outstanding portfolio of top technologies that we're further developing," added Kaeser.

"The public listing is a key lever for reaching our strategic goal of being THE enabler for healthcare providers worldwide," said Bernd Montag, CEO of Siemens Healthineers. "Greater entrepreneurial freedom and agility will allow us to help shape the development of the global healthcare market and the growth strategies of successful healthcare providers. We'll enable our customers to participate successfully in the trends toward consolidation, industrialization and holistic health management with a high degree of clinical relevance, efficient workflows and financial value added."

Related Links:
Siemens
Siemens Healthineers

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Myocardial Infarction Test
Finecare cTn I/NT-proBNP Rapid Quantitative Test
New
Mini Vortex Mixer
Vornado
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Schematic overview of the deep learning-based circulating exosome analysis for lung cancer detection (Photo courtesy of Chuan Xu, Cheng Jiang)

Liquid Biopsy Approach to Transform Diagnosis, Monitoring and Treatment of Lung Cancer

Lung cancer continues to be a major contributor to cancer-related deaths globally, with its biological complexity and diverse regulatory processes making diagnosis and treatment particularly difficult.... Read more

Pathology

view channel
Image: The Aiforia Breast Cancer Grading AI solution is CE-IVD marked (Photo courtesy of Aiforia Technologies)

Clinical AI Solution for Automatic Breast Cancer Grading Improves Diagnostic Accuracy

Labs that use traditional image analysis methods often suffer from bottlenecks and delays. By digitizing their pathology practices, labs can streamline their work, allowing them to take on larger caseloads... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.